Clinical trials: Metastatic NSCLC
Non-Small Cell Lung Cancer, NSCLC
A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC
The purpose of this study is to determine whether the combination of MM-121 plus docetaxel is more effective than docetaxel alone in regards to PFS in patients with heregulin-positive NSCLC.
- Conditions
- Non-Small Cell Lung Cancer, NSCLC, Adenocarcinoma, Heregulin
- Trial name
- SHERLOC (NCT02387216)
- Testing
- MM-121, Docetaxel
- Where
- 35 sites in United States, Canada and 4 more
- Volunteers
- 153 people
- Sponsor
- Elevation Oncology
Non-small Cell Lung Cancer
Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC
Erlotinib is a drug which targets non small cell lung cancer with a genetic change (mutation) in the epidermal growth factor receptor (EGFR).
- Trial name
- NCT00997334
- Testing
- Erlotinib
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- David M. Jackman, MD
Advanced or Metastatic Solid Tumors, Ovarian Cancer
A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors
This research study is studying a new drug, NC762, as a possible treatment for advanced or metastatic solid tumors.
- Conditions
- Advanced or Metastatic Solid Tumors, Ovarian Cancer, Non-small Cell Lung Cancer, Breast Cancer
- Trial name
- NCT04875806
- Testing
- NC762
- Where
- 8 sites in United States
- Volunteers
- 40 people
- Sponsor
- NextCure, Inc.
Kidney Cancer, Lung Cancer
Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer
RATIONALE: Cryotherapy kills tumor cells by freezing them. Giving an injection of GM-CSF before cryotherapy and inhaling GM-CSF after cryotherapy may interfere with the growth of tumor cells and shrink the tumor.
- Conditions
- Kidney Cancer, Lung Cancer, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00514215
- Testing
- sargramostim, flow cytometry, immunoenzyme technique
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Non-small Cell Lung Cancer (NSCLC), Lung Cancer
Phase 2 Trial of Bevacizumab in Combination With Pemetrexed
This trial evaluated the safety of combining bevacizumab and pemetrexed in non-small cell lung cancer (NSCLC) patients with stable brain metastases as second-line chemotherapy, while evaluating progression-free survival (PFS) and…
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Lung Cancer, Neoplasm Metastasis
- Trial name
- NCT00227019
- Testing
- Bevacizumab, Pemetrexed, Vitamin B12
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Heather Wakelee
Advanced/Metastatic Non-Small Cell Lung Cancer
A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer
The purpose of this study is to determine whether progression-free survival with ixabepilone is superior to that achieved with paclitaxel plus carboplatin in participants with advanced nonsmall-cell lung cancer and beta III…
- Trial name
- NCT00723957
- Testing
- Ixabepilone, 32 mg/m^2, Paclitaxel, 200 mg/m^2, Carboplatin (area under the concentration curve [AUC] 6)
- Where
- 33 sites in United States, Argentina and 8 more
- Volunteers
- 260 people
- Sponsor
- R-Pharm
Carcinoma, Non-Small-Cell Lung, Lung Diseases
Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC
This is a multicohort phase 2 study to evaluate the efficacy of pembrolizumab combined with the investigational drug sitravatinib in the frontline treatment of advanced, non-squamous PD-L1 positive NSCLC.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Metastatic Lung Non-Small Cell Carcinoma
- Trial name
- NCT04925986
- Testing
- Sitravatinib, Pembrolizumab
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Sarah Goldberg
Non-Small Cell Lung Cancer
A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy
This Phase III, global, multicenter, open-label, randomized, controlled study will evaluate the efficacy and safety of atezolizumab (an anti-programmed death-ligand 1 [anti-PD-L1] antibody) compared with a single agent…
- Trial name
- IPSOS (NCT03191786)
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Vinorelbine, Gemcitabine
- Where
- 91 sites in Argentina, Belgium and 22 more
- Volunteers
- 453 people
- Sponsor
- Hoffmann-La Roche
Non-Small Cell Lung Cancer
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)
The reason for the study is to find out if an experimental combination of an oral medication called osimertinib (TAGRISSO®) when used in combination with chemotherapy is more effective than giving osimertinib alone for the…
- Trial name
- FLAURA2 (NCT04035486)
- Testing
- Osimertinib, Pemetrexed/Carboplatin, Pemetrexed/Cisplatin
- Where
- 153 sites in United States, Argentina and 19 more
- Volunteers
- 587 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung
Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations
The main aim of this study is to evaluate the safety and tolerability of afatinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring Epidermal Growth Factor Receptor (EGFR) mutation(s)…
- Trial name
- NCT02044380
- Testing
- Afatinib
- Where
- 5 sites in Canada
- Volunteers
- 14 people
- Sponsor
- Boehringer Ingelheim
Locally Advanced or Metastatic NSCLC
Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation
This is a single-arm, non-randomized multicentre phase 2 study in NSCLC patients with EGFR exon 20 insertion mutation, whose disease has progressed on standard chemotherapy.
- Trial name
- NCT03414814
- Testing
- Osimertinib 80 MG [Tagrisso]
- Where
- South Korea
- Volunteers
- 15 people
- Sponsor
- Seoul National University Hospital
Lung Cancer Metastatic
A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC
This is a research study to find out the safety and tolerability of combining the drug evolucumab with standard immunotherapy in people with advanced lung cancer (a type called non-small cell lung cancer).
- Trial name
- TOP2101 (NCT05144529)
- Testing
- Nivolumab, Ipilimumab, Evolocumab
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Eziafa Oduah, MD, PhD, MPH
Adult Giant Cell Glioblastoma, Adult Glioblastoma
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer patients. The uptake of the novel radiopharmaceutical 18F-FPPRGD2 will be assessed in study participants with glioblastoma multiforme…
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Male Breast Cancer
- Trial name
- NCT01806675
- Testing
- 18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sanjiv Sam Gambhir
Carcinoma, Non-Small-Cell Lung
Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation
The purpose of the study was to learn whether the study drug (capmatinib) helps to control lung cancer better compared to a single agent chemotherapy (docetaxel) and whether it is safe when given to patients suffering from a…
- Trial name
- GeoMETry-III (NCT04427072)
- Testing
- Capmatinib, Docetaxel
- Where
- 43 sites in Belgium, Brazil and 16 more
- Volunteers
- 22 people
- Sponsor
- Novartis Pharmaceuticals
Lung Cancer, Lung Cancer Metastatic
Pembro+Chemo in Brain Mets
The goal of this study is to evaluate whether providing Pembrolizumab prolongs survival and preserves quality of life while minimizing side effects for patients with NSCLC with untreated asymptomatic brain metastasis.
- Conditions
- Lung Cancer, Lung Cancer Metastatic, Brain Cancer, Cancer
- Trial name
- NCT04964960
- Testing
- Pembrolizumab, Nab paclitaxel, Paclitaxel
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- John L. Villano, MD, PhD
Non Small Cell Lung Cancer, Metastatic NSCLC
Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer
This open-label, non-randomized Phase II trial is designed to assess the safety and tolerability of GT103 in combination with pembrolizumab in adult subjects with relapsed or refractory, metastatic NSCLC.
- Conditions
- Non Small Cell Lung Cancer, Metastatic NSCLC, Recurrent Non Small Cell Lung Cancer
- Trial name
- NCT05617313
- Testing
- Pembrolizumab, GT103
- Where
- 6 sites in United States
- Volunteers
- 21 people
- Sponsor
- Ryan Dackor
Carcinoma, Non-Small-Cell Lung
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
The purpose of this study is to assess the efficacy of the amivantamab and lazertinib combination, compared with osimertinib, in participants with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions [Exon 19del]…
- Trial name
- MARIPOSA (NCT04487080)
- Testing
- Amivantamab, Osimertinib, Lazertinib
- Where
- 269 sites in United States, Argentina and 26 more
- Volunteers
- 1,074 people
- Sponsor
- Janssen Research & Development, LLC
Non-small Cell Lung Cancer, Efficacy
Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced NSCLC Metastatic Non-small Cell Lung Cancer
A phase III trial has demonstrated that in advanced non-small cell lung cancer (NSCLC) cisplatin/ pemetrexed provides similar efficacy with better tolerability and more convenient administration than cisplatin/gemcitabine.
- Trial name
- AP/GP (NCT01194453)
- Testing
- cisplatin, dexamethasone,vitamin B12, folic acid, cisplatin, gemcitabine
- Where
- China
- Volunteers
- 288 people
- Sponsor
- Sun Yat-sen University
Locally Advanced Solid Tumor, Metastatic Cancer
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
This is a Phase 1, open-label, first-in-human study of CTX-471 administered as a monotherapy or in combination with pembrolizumab in patients with metastatic or locally advanced malignancies that have progressed while receiving…
- Conditions
- Locally Advanced Solid Tumor, Metastatic Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT03881488
- Testing
- CTX-471, Pembrolizumab (KEYTRUDA®)
- Where
- 10 sites in United States
- Volunteers
- 100 people
- Sponsor
- Compass Therapeutics
Metastatic Non-Small Cell Lung Cancer
Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)
This study will evaluate the efficacy and safety of pembrolizumab (MK-3475) with lenvatinib (E7080/MK-7902) vs. docetaxel in participants with metastatic non-small cell lung cancer (NSCLC) and progressive disease (PD) after…
- Trial name
- NCT03976375
- Testing
- Pembrolizumab, Lenvatinib, Docetaxel
- Where
- 143 sites in United States, Argentina and 16 more
- Volunteers
- 422 people
- Sponsor
- Merck Sharp & Dohme LLC